GlassScriptPhysician profile
Thirosha Thirunavukarasu
NPI 1003340621
$4,607.03
in general payments reported to CMS, 2019-2025
39 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.58 · 2021: $269 · 2022: $772 · 2023: $618 · 2024: $1,705 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.86 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $482.78 | 2021-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.88 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $403.79 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.94 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $220.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $192.20 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $172.64 | 2021-2025 | |
| Corium, LLC | $168.92 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $144.05 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $123.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $103.12 | 2022-2025 | Ajovy, Austedo Xr |
| Abbott Laboratories | $90.48 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $89.50 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $79.64 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.40 | 2024 | |
| Glaxosmithkline, LLC. | $57.21 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $51.65 | 2024-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.07 | 2024-2025 | Caplyta |
| Boston Scientific Corporation | $46.75 | 2024-2025 | General - Pain Management, Watchman Flx |
| Dynavax Technologies Corporation | $45.47 | 2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $42.80 | 2023-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $41.78 | 2023-2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $37.60 | 2024-2025 | Voquezna |
| Lundbeck LLC | $34.12 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $32.21 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $31.43 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $28.16 | 2025 | Unithroid |
| Actelion Pharmaceuticals US, INC. | $26.32 | 2024 | Uptravi, Opsumit |
| Eisai INC. | $24.11 | 2025 | |
| Daiichi Sankyo INC. | $23.13 | 2022 | |
| Astellas Pharma US INC | $23.00 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $19.46 | 2021 | |
| Ardelyx, INC. | $17.06 | 2024 | Ibsrela |
| Mylan Specialty L.P. | $16.72 | 2023 | Yupelri |
| Axsome Therapeutics, INC. | $15.12 | 2024 | Auvelity |
| Philips North America LLC | $14.90 | 2024 | (Ck6) Holter |
| Watermark Medical, INC. | $13.92 | 2024 | |
| Abiomed | $13.46 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thirosha Thirunavukarasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.